Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001213900-24-078635
Filing Date
2024-09-13
Accepted
2024-09-13 16:57:00
Documents
1
Group Members
FAIRMOUNT HEALTHCARE CO-INVEST III L.P.FAIRMOUNT HEALTHCARE FUND II L.P.PETER HARWINTOMAS KISELAK

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO SCHEDULE 13D ea0214512-13da1fair_oruka.htm SC 13D/A 131942
  Complete submission text file 0001213900-24-078635.txt   134023
Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Subject) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-51477 | Film No.: 241298450
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)

Mailing Address 200 BARR HARBOR DRIVE SUITE 400 WEST CONSHOHOCKEN PA 19428
Business Address 200 BARR HARBOR DRIVE SUITE 400 WEST CONSHOHOCKEN PA 19428 267-262-5300
Fairmount Funds Management LLC (Filed by) CIK: 0001802528 (see all company filings)

EIN.: 364841215 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A